Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CALC CalciMedica	$3.26 +3.2%	$3.02	$1.42 ▼ $5.65	$44.22M	1.34	64,799 shs	40,914 shs
FTLF FitLife Brands	$20.15 +2.3%	$18.23	$9.83 ▼ $20.98	$185M	0.65	15,561 shs	19,488 shs
SXTC China SXT Pharmaceuticals	$1.45 -1.9%	$1.61	$0.95 ▼ $7.84	$171.49M	1.36	63,957 shs	11,937 shs
TARA Protara Therapeutics	$5.34 +2.3%	$3.59	$1.68 ▼ $10.48	$201.40M	1.53	828,362 shs	534,137 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CALC CalciMedica	+3.16%	+0.31%	+2.84%	+59.02%	-14.44%
FTLF FitLife Brands	+2.28%	+2.08%	+14.23%	+52.77%	+26.03%
SXTC China SXT Pharmaceuticals	-1.89%	-11.04%	-26.77%	-13.07%	-68.21%
TARA Protara Therapeutics	+2.30%	+9.65%	+70.06%	+75.08%	+217.86%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CALC CalciMedica	$3.26 +3.2%	$3.02	$1.42 ▼ $5.65	$44.22M	1.34	64,799 shs	40,914 shs
FTLF FitLife Brands	$20.15 +2.3%	$18.23	$9.83 ▼ $20.98	$185M	0.65	15,561 shs	19,488 shs
SXTC China SXT Pharmaceuticals	$1.45 -1.9%	$1.61	$0.95 ▼ $7.84	$171.49M	1.36	63,957 shs	11,937 shs
TARA Protara Therapeutics	$5.34 +2.3%	$3.59	$1.68 ▼ $10.48	$201.40M	1.53	828,362 shs	534,137 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CALC CalciMedica	+3.16%	+0.31%	+2.84%	+59.02%	-14.44%
FTLF FitLife Brands	+2.28%	+2.08%	+14.23%	+52.77%	+26.03%
SXTC China SXT Pharmaceuticals	-1.89%	-11.04%	-26.77%	-13.07%	-68.21%
TARA Protara Therapeutics	+2.30%	+9.65%	+70.06%	+75.08%	+217.86%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CALC CalciMedica	2.00	Hold	$16.00	390.80% Upside
FTLF FitLife Brands	3.00	Buy	$23.00	14.14% Upside
SXTC China SXT Pharmaceuticals	1.00	Sell	N/A	N/A
TARA Protara Therapeutics	2.86	Moderate Buy	$19.60	267.04% Upside

Current Analyst Ratings Breakdown

Latest CALC, SXTC, FTLF, and TARA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/8/2025	CALC CalciMedica	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
10/8/2025	FTLF FitLife Brands	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C+)
10/8/2025	SXTC China SXT Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
10/8/2025	TARA Protara Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
10/6/2025	FTLF FitLife Brands	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
9/27/2025	CALC CalciMedica	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/27/2025	FTLF FitLife Brands	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C+)
9/27/2025	SXTC China SXT Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
9/27/2025	TARA Protara Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/4/2025	FTLF FitLife Brands	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/15/2025	FTLF FitLife Brands	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$20.00 ➝ $25.00

(Data available from 10/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CALC CalciMedica	N/A	N/A	N/A	N/A	$1.07 per share	N/A
FTLF FitLife Brands	$64.47M	2.93	$1.04 per share	19.44	$3.93 per share	5.13
SXTC China SXT Pharmaceuticals	$1.74M	96.69	N/A	N/A	$21.35 per share	0.07
TARA Protara Therapeutics	N/A	N/A	N/A	N/A	$4.77 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CALC CalciMedica	-$13.70M	-$1.60	N/A	N/A	N/A	N/A	-206.51%	-103.81%	11/12/2025 (Estimated)
FTLF FitLife Brands	$8.98M	$0.84	23.99	18.32	N/A	12.63%	21.70%	13.45%	N/A
SXTC China SXT Pharmaceuticals	-$3.30M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
TARA Protara Therapeutics	-$44.60M	-$1.62	N/A	N/A	N/A	N/A	-36.87%	-33.85%	11/11/2025 (Estimated)

Latest CALC, SXTC, FTLF, and TARA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/11/2025	Q3 2025	TARA Protara Therapeutics	-$0.39	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q2 2025	FTLF FitLife Brands	$0.18	$0.18	N/A	$0.18	$16.17 million	$16.13 million
8/12/2025	Q2 2025	CALC CalciMedica	-$0.40	-$0.40	N/A	-$0.40	N/A	N/A
8/11/2025	Q2 2025	TARA Protara Therapeutics	-$0.43	-$0.35	+$0.08	-$0.35	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CALC CalciMedica	N/A	N/A	N/A	N/A	N/A
FTLF FitLife Brands	N/A	N/A	N/A	N/A	N/A
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TARA Protara Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CALC CalciMedica	1.39	5.45	5.45
FTLF FitLife Brands	0.15	1.71	0.81
SXTC China SXT Pharmaceuticals	0.01	3.54	3.40
TARA Protara Therapeutics	N/A	12.81	12.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CALC CalciMedica	N/A
FTLF FitLife Brands	2.32%
SXTC China SXT Pharmaceuticals	5.02%
TARA Protara Therapeutics	38.13%

Insider Ownership

Company	Insider Ownership
CALC CalciMedica	41.55%
FTLF FitLife Brands	61.40%
SXTC China SXT Pharmaceuticals	3.95%
TARA Protara Therapeutics	12.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CALC CalciMedica	30	13.97 million	8.17 million	No Data
FTLF FitLife Brands	20	9.39 million	3.63 million	Not Optionable
SXTC China SXT Pharmaceuticals	90	116.03 million	111.45 million	Not Optionable
TARA Protara Therapeutics	30	38.58 million	33.76 million	Optionable

CALC, SXTC, FTLF, and TARA Headlines

Recent News About These Companies

Weiss Ratings Reaffirms Sell (D-) Rating for Protara Therapeutics (NASDAQ:TARA)

October 9, 2025 | americanbankingnews.com

Protara Therapeutics' (TARA) "Sell (D-)" Rating Reiterated at Weiss Ratings

October 9, 2025 | marketbeat.com

Protara Therapeutics, Inc. (NASDAQ:TARA) Receives Average Rating of "Moderate Buy" from Analysts

October 8, 2025 | americanbankingnews.com

Protara Therapeutics, Inc. (NASDAQ:TARA) Given Consensus Recommendation of "Moderate Buy" by Brokerages

October 8, 2025 | marketbeat.com

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 1, 2025 | globenewswire.com

A Fresh Look at Protara Therapeutics (TARA) Valuation After Joining the S&P Global BMI Index

September 24, 2025 | finance.yahoo.com

What Protara Therapeutics (TARA)'s S&P Global BMI Inclusion Means For Shareholders

September 22, 2025 | finance.yahoo.com

Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA) and Zymeworks (ZYME)

September 21, 2025 | theglobeandmail.com

Identifying Undervalued and Overlooked Assets to Address Unmet Patient Needs

September 15, 2025 | fiercebiotech.comF

Protara Therapeutics, Inc. (NASDAQ:TARA) Given Average Recommendation of "Buy" by Brokerages

September 15, 2025 | marketbeat.com

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 2, 2025 | globenewswire.com

Protara Therapeutics to Participate in Upcoming Investor Conferences

August 27, 2025 | globenewswire.com

We're Not Very Worried About Protara Therapeutics' (NASDAQ:TARA) Cash Burn Rate

August 13, 2025 | finance.yahoo.com

Protara Therapeutics Reports Q2 2025 Financial Results

August 12, 2025 | msn.com

Protara Beats Q2 Loss Estimates

August 11, 2025 | aol.comA

Protara Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update

August 11, 2025 | globenewswire.com

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 1, 2025 | gurufocus.com

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 1, 2025 | globenewswire.com

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635 (c) (4) - The Manila Times

July 2, 2025 | manilatimes.netM

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635 (c) (4) - Morningstar

July 2, 2025 | morningstar.comM

Protara Therapeutics, Inc. Added to Russell 3000® Index, Enhancing Visibility in Financial Community - Nasdaq

July 2, 2025 | nasdaq.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CALC, SXTC, FTLF, and TARA Company Descriptions

CalciMedica NASDAQ:CALC

$3.26 +0.10 (+3.16%)

Closing price 10/13/2025 03:59 PM Eastern

Extended Trading

$3.23 -0.03 (-0.92%)

As of 10/13/2025 05:18 PM Eastern

CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.

FitLife Brands NASDAQ:FTLF

$20.15 +0.45 (+2.28%)

Closing price 10/13/2025 04:00 PM Eastern

Extended Trading

$20.14 0.00 (-0.02%)

As of 10/13/2025 04:10 PM Eastern

FitLife Brands, Inc. provides nutritional supplements for health-conscious consumers in the United States and internationally. The company provides weight loss, sports nutrition, and general health products; sports nutrition products; weight loss and sports nutrition products; sports nutrition and general wellness formulations with an emphasis on natural, vegan, and organic ingredients; and male health and weight loss products, as well as other diet, health, and sports nutrition supplements and related products; and value-oriented sports nutrition and weight loss products. It offers MRC products which includes general health supplements; and natural skincare and beauty products. In addition, it markets its products under the brand names of NDS Nutrition, PMD Sports, SirenLabs, CoreActive, Nutrology, Metis Nutrition, iSatori, BioGenetic Laboratories, Energize, Dr. Tobias, All-Natural Advice, and Maritime Naturals through franchised stores, as well as through retail locations, which include specialty, mass, and online. The company was formerly known as Bond Laboratories, Inc. and changed its name to FitLife Brands, Inc. in September 2013. FitLife Brands, Inc. was incorporated in 2005 and is headquartered in Omaha, Nebraska.

China SXT Pharmaceuticals NASDAQ:SXTC

$1.45 -0.03 (-1.89%)

Closing price 10/13/2025 03:59 PM Eastern

Extended Trading

$1.44 0.00 (-0.34%)

As of 10/13/2025 07:17 PM Eastern

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals in 10 provinces and municipalities in China. China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.

Protara Therapeutics NASDAQ:TARA

$5.34 +0.12 (+2.30%)

Closing price 10/13/2025 04:00 PM Eastern

Extended Trading

$5.41 +0.07 (+1.39%)

As of 10/13/2025 07:57 PM Eastern

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CALC, SXTC, FTLF, and TARA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CALC, SXTC, FTLF, and TARA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CALC, SXTC, FTLF, and TARA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CALC, SXTC, FTLF, and TARA Company Descriptions

CalciMedica NASDAQ:CALC

FitLife Brands NASDAQ:FTLF

China SXT Pharmaceuticals NASDAQ:SXTC

Protara Therapeutics NASDAQ:TARA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CALC, SXTC, FTLF, and TARA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CALC, SXTC, FTLF, and TARA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CALC, SXTC, FTLF, and TARA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CALC, SXTC, FTLF, and TARA Company Descriptions

CalciMedica NASDAQ:CALC

FitLife Brands NASDAQ:FTLF

China SXT Pharmaceuticals NASDAQ:SXTC

Protara Therapeutics NASDAQ:TARA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools